Core Viewpoint - The company, Pruis, established in 2013 and listed in 2022, is a leading SMO enterprise in China, specializing in technology development and consulting in the pharmaceutical sector, with a strong project management and quality control capability [1] Financial Performance - In Q3 2025, Pruis achieved a revenue of 609 million yuan, ranking 14th in the industry, significantly lower than the top competitor WuXi AppTec's 32.857 billion yuan and second-place Kanglong Chemical's 10.086 billion yuan [2] - The net profit for the same period was 87.3815 million yuan, also ranking 14th, and below the industry average of 58.5 million yuan [2] Financial Ratios - As of Q3 2025, Pruis had a debt-to-asset ratio of 16.69%, lower than the industry average of 22.79%, indicating good solvency [3] - The gross profit margin was 25.58%, which, while improved from 24.52% year-on-year, remains below the industry average of 37.70% [3] Executive Compensation - The chairman, Lai Chunbao, received a salary of 496,500 yuan in 2024, a decrease from 513,000 yuan in 2023 [4] - The general manager, Yang Hongwei, earned 1.6174 million yuan in 2024, down from 1.6387 million yuan in 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 0.20% to 8,588, while the average number of shares held per shareholder decreased by 0.20% to 8,770.25 [5] - Notable changes among the top ten shareholders include the entry of Noan Pioneer Mixed A as the fifth-largest shareholder and a significant reduction in holdings by Tianhong Medical Health A [5] Business Outlook - According to Changcheng Guorui Securities, Pruis's performance in the first half of 2025 showed improvement, with new orders growing rapidly, including a 40.12% year-on-year increase in new contracts totaling 600 million yuan [5] - The company is expected to see revenue growth, with projected net profits of 121 million yuan, 131 million yuan, and 141 million yuan for 2025 to 2027, respectively [5] - Xinda Securities noted significant improvements in Q2 2025, with a total of 4,157 employees and nearly 4,000 in business roles, serving over 960 clinical trial institutions across more than 200 cities [6] - The company has established a comprehensive quality control system with over 280 SOP documents, maintaining a strong reputation in project execution [6]
普蕊斯的前世今生：2025年三季度营收6.09亿行业排14，净利润8738.15万行业居14